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Abstract 
Background: Inguinal orchiectomy is curative in 70–80% of clinical stage I testicular germ cell tumours (CS I TGCT). 
The identification of patients who are at low risk of relapse is critical to avoid unnecessary treatment. The aim of this 
study is to explore EGFR, hMLH‑1/hMSH‑2 and microsatellite instability (MSI) as potential prognostic factors of recur‑
rence in CS I TGCT.
Methods: Fifty‑six CS I TGCT patients who underwent inguinal orchiectomy were included in this study. We analysed 
the relationship between clinicopathological and molecular factors with survival. Analysis of hMLH1, hMSH2 and EGFR 
expression was carried out by immunohistochemistry. Methylation status of the hMLH1 promoter was determined 
by pyrosequencing analysis in selected cases. EGFR exons 19, 20, 21 were analysed by PCR labeled‑fragments and MSI 
status was determined using standard Multiplex MSI assays.
Results: Classical pathological factors such as lymphovascular invasion, high percentage of embryonal carcinoma, 
rete testis invasion or tumour size ≥4 cm showed a significant relationship with a higher risk of relapse. Additionally, 
it was found that an epididymis invasion proved to be a significant independent poor prognostic factor of recurrence 
(p = 0.001). hMLH1 or hMSH2 expression showed no significant association with risk of relapse and no MSI was found. 
EGFR expression was observed in 30.4% of samples and its expression was associated with higher risk of relapse (HR 
3.5; 95% CI 1.3–9.8; p = 0.016). None of the cases presented EGFR kinase domain mutations.
Conclusions: Epididymis invasion and EGFR expression, but not hMLH‑1/hMSH‑2 or MSI, could be potentially useful 
as new prognostic factors of recurrence for CS I TGCT.
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Background
Testicular germ cell tumour (TGCT) is the most com-
mon solid malignant neoplasm among young men in 
Western countries [1]. Overall approximately two-thirds 
of patients have clinical stage I (CS I) disease at the time 
of diagnosis. In patients with CS I TGCT, radical inguinal 
orchiectomy is the treatment of choice and offers a cure 
rate of 70–80% [2, 3]. Current management after orchi-
ectomy includes radiotherapy, retroperitoneal lymphad-
enectomy, adjuvant chemotherapy or surveillance with 
chemotherapy at relapse. All options have demonstrated 
to provide an overall survival (OS) of over 97% [4, 5]. 
However, in recent decades efforts have been made to 
reduce treatment-related morbidity and tailor adju-
vant treatments to those patients who are at high-risk of 
relapse. Prognostic factors as lymphovascular invasion 
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testis invasion and tumour size have been proposed to 
stratify patients into low and high-risk groups [4, 6, 7]. 
Nevertheless, several studies have reported the limited 
predictive value of these factors and only LVI is widely 
accepted [4, 8, 9].
New insights into the molecular biology of cancer 
have opened up new fields of research and new genetic 
and molecular prognostic factors have emerged. One 
attractive new area is DNA damage repair, where one 
of the most well known repair pathways is mismatch 
repair (MMR). Inactivation of MMR genes leads to 
genetic instability, characterized by small deletions or 
expansions within small repetitive sequences of DNA 
called microsatellites. This abnormality is known as 
microsatellite instability (MSI). MMR deficiency and 
MSI have been reported in TGCT [10–14]. Further-
more, a relationship between TGCT MSI and/or MMR 
deficiency and survival/resistance to cisplatin-based 
chemotherapy has been demonstrated in some studies 
[12–14].
Another promising group of molecular prognos-
tic factors in oncology are growth factor receptors, and 
especially the epidermal growth factor receptor family 
member 1 (EGFR, also known as HER1 or ERBB1). EGFR 
is able to induce cancer through three different mecha-
nisms: activating mutations in the catalytic domain, gene 
amplification or protein overexpression. Among the most 
widely studied mutations are a deletion in exon 19, an 
insertion in exon 20, and a missense mutation in exon 
21, which increase the kinase activity of this growth fac-
tor receptor, conferring it with oncogenic properties [15]. 
EGFR expression is elevated in many tumours, which 
correlates with poor clinical outcome in some cases [16, 
17].
In relation to TGCT, the role of EGFR is still not firmly 
established. Some studies have reported the expression 
of EGFR in 40–50% of TGCT [18–23]. Furthermore, the 
expression of EGFR ligands (EGF and TGF-α) has been 
reported in TGCTs EGFR+, suggesting a mechanism of 
cell autocrine stimulation [18]. In addition, the relation 
between EGFR expression and prognosis or resistance to 
cisplatin in advanced TGCT have been studied, with con-
tradictory results [19, 21].
In the current study, we performed a histological 
review of surgically resected specimens from primary CS 
I TGCT who underwent inguinal orchiectomy. In order 
to determine new prognostic factors in these kinds of 
tumours we analysed the relationship between relapse-
free survival (RFS) and molecular factors including MSI 
status, hMLH-1/hMSH-2 expression, EGFR catalytic 
domain mutations and EGFR expression.
Methods
Patients
Patients treated consecutively in our institution from 
1976 to May 2016 were identified. The cases were eli-
gible if they had (1) histological confirmation of TGCT 
and clinical stage I according to the American Joint 
Committee on Cancer (2010 edition) TNM classifica-
tion (confirmed retrospectively); (2) radical inguinal 
orchiectomy; (3) negative levels of alpha-fetoprotein 
(AFP) or beta-human chorionic gonadotropin (B-HCG) 
3  weeks after orchiectomy; (4) No neoadjuvant treat-
ment or adjuvant treatment; (5) at least 1  year of 
follow-up.
Outpatient visits were monthly in the first year, every 
3 months in the second year, each 6 months in the third 
to fifth year and one per year until the tenth year. At each 
visit serum AFP and B-HCG were measured and chest 
X-rays and physical examinations were performed. A 
computed tomography (CT) scan was performed every 
3 months the first year, every 6 months the second year 
and once per year after the fifth year. Recurrent disease 
was defined as elevated serum tumour markers (AFP, 
B-HCG) or tumour growth as seen by radiographic 
study. The samples for the study were obtained through 
the Principado de Asturias biorepository and all patients 
signed a written consent.
Tissue samples
Formalin-fixed paraffin-embedded tissue samples were 
retrospectively collected. The histopathological lesions of 
interest were analysed to select the area with more than 
80% of malignant cells. All cases were reviewed by the 
same pathologist (AA) and classified according to WHO 
criteria. Histopathological review of the testis tumour 
included tumour size, presence or absence of LVI, rete 
testis invasion, epididymis invasion (EI) and predomi-
nant histological subtype. Three sections cut from tissue 
blocks of 0.1 mm each were mounted on tissue microar-
ray (TMA) blocks. TMA block sections 3-μm thick were 
mounted on REAL™ Capillary Gap Microscope Slides 
(DAKO) in preparation for immunohistochemistry 
(IHC). Additional sections  0.2  mm thick were taken for 
genetic analysis.
Immunochemistry studies
Immunohistochemical analysis was performed using the 
EGFR pharm Dx™ kit (DAKO, Glostrup, Denmark) and 
the EnVision™ FLEX kit (DAKO), according to the manu-
facturer’s instructions.
The sections were incubated with primary antibod-
ies against hMLH1 (mouse anti-hMHL1: clone ES05 
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(DAKO), diluted 1:50, 30  min RT), hMSH2 (mouse 
anti-hMSH2: clone FE11 (Invitrogen), diluted 1:100, 
20 min RT) and EGFR (mouse anti-EGFR: clone 2-18C9 
(DAKO), diluted 1:100, 30 min RT).
The extent of staining was evaluated by visual exami-
nation microscopically. Nuclear staining (hMLH1 and 
hMSH2) was scored as “normal”, “low,” or “absent” com-
pared with internal positive controls, according to previ-
ous scoring systems [12, 13]. In the EGFR analysis, the 
scoring system recommended by Tsao et al. [24] was fol-
lowed and results were recorded as positive (staining of 
≥10% of membrane cells) or negative (staining of <10% of 
membrane cells).
Genomic DNA analysis
Following deparaffinization in xylenes and ethanol, 
DNA was extracted from the tissue scrapings using the 
QIAamp DNA Mini kit (Qiagen, Valencia, CA, USA).
All PCRs were carried out using Gene Amp® Polymer-
ase Chain Reaction (PCR) Systems 9700 (Applied Bio-
systems, Foster City, CA, USA). Negative controls were 
included in each set of amplifications.
All PCR data were subsequently analysed on an 
ABI PRISM® 310 Genetic Analyzer using capillary 
electrophoresis.
EGFR exon analysis
PCR and fragment analysis were performed as described 
previously [25], with slight modifications. Fragments 
of EGFR exons 19, 20 and 21 were amplified using the 
primer-pairs listed in Additional file 1: Table S1. The for-
ward primers specific for exons 19 and 20 were labeled 
with 6-carboxyfluorescein (6-FAM) at the 5′-end. The 
expected amplicon size for exon 19 is 145 bp; a smaller 
size indicates the presence of a deletion. The expected 
amplicon size for exon 20 is 204 bp; the resulting ampli-
con will be larger if an insertion has occurred. To detect 
the p.L858R mutation in exon 21, an allele-specific oli-
gonucleotide PCR was performed. Three primers were 
used to amplify the region encompassing the mutation. 
The reverse primer is labeled with 5′HEX. The expected 
amplicon size for exon 21 is 216 bp. If the L858R muta-
tion is present, the allele-specific forward primer creates 
an additional amplicon of 147 bp.
Following PCR, 2 µl of product and 0.5 µl of GeneScan 
500-LIZ molecular weight standard (Applied Biosystems, 
Madrid, Spain) were denatured in 15  µl of formamide 
at 95  °C for 10  min. Separation was achieved using a 
four-color laser induced fluorescence capillary electro-
phoresis system: ABI PRISM® 310 (Applied Biosystems, 
Madrid, MA, Spain) with POP4 polymer. Evaluation was 
performed using GeneMapper v.3.7 software (Applied 
Biosystems).
Microsatellite analysis
Multiplex analysis of MSI status of all tumour DNA sam-
ples analysed in this study was determined with the MSI 
Analysis System Version 1.2 (Promega). The MSI Analy-
sis System consists of five nearly monomorphic mononu-
cleotide markers (BAT-25, BAT-26, NR-21, NR-24, and 
MONO-27) for MSI determination and two polymorphic 
pentanucleotide markers (Penta C and Penta D) for each 
sample identification.
We interpreted MSI instability as high when present 
at ≥2 microsatellite loci, low when present at a single 
microsatellite locus and stable (MSS) when no instability 
at any of the loci assessed was found, as established in the 
Revised Bethesda Guidelines [26].
Methylation of hMLH‑1 promoter
The methylation status of hMLH-1 genes was analysed 
using a methylation-specific polymerase chain reaction 
(MSP) assay. Bisulfite modification of genomic DNA was 
carried out with the EZ DNA Methylation-GoldTM Kit 
(Zymo Research Corporation) following the manufactur-
er’s protocol.
The pyrosequencing reaction was performed on a 
PyroMark Q24 MDx Vacuum Workstation (Qiagen) 
using Pyro Gold Q24 Reagents (Qiagen) and Streptavidin 
Sepharose HP (Amersham Biosciences). Purification and 
subsequent processing of the biotinylated single-stranded 
DNA was performed according to the manufacturer’s 
recommendations. The pyrosequencing primers were 
used in a final concentration of 0.5 μmol/l. Resulting data 
were analysed and quantified with the PyroMark Q24 
software version 2.0.6 (Qiagen). This software calculates 
the methylation percentage (mC/(mC + C)) for each of 
the 5 CpG islands present in the hMLH-1 promoter. The 
methylation score was given as a percentage of methyla-
tion on each locus, obtained by adding the percentages 
of each CpG on each locus. A total methylation of 15% 
was used as threshold for hMLH1 hypermethylation, as 
previously reported [27].
Statistical methods
Relapse-free survival (RFS) and overall survival (OS) curves 
were estimated by the Kaplan–Meier method. Comparison 
of resulting relapse-free survival curves were performed 
using the log-rank test. Univariate and multivariate analysis 
was performed using the Cox proportional hazards regres-
sion model [28]. Probability values (P values) lower than 
0.05 were considered statistically significant.
Results
Patients and specimens
Fifty-six patients with CS I TGCTs treated in our insti-
tution were included in this study. All underwent radical 
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orchiectomy. Baseline patient and tumour characteristics 
are summarized in Table 1.
Out of all the patients, 26.8% (15 from 56) relapsed with 
a median follow-up of 5.2  years (SD 4.3). All relapsed 
cases were rescued with platinum-based chemotherapy. 
Five-year estimated relapse-free survival and overall sur-
vival was 73.2 and 100% respectively.
MMR immunostaining, hMLH1 promoter methylation 
and MSI analysis
Immunostaining of hMLH1 and hMSH2 showed an 
intense hMLH1 and hMSH2 nuclear staining in most 
cases, regardless of the histology (Additional file  2: 
Table  S2). hMLH-1 expression was considered null or 
low in 27 (48.2%) cases and hMSH-2 in 16 (28.6%) cases 
(representative samples shown in Fig. 1a–d).
In order to find an epigenetic mechanism to explain a 
gradual expression of MMR proteins, we selected absent 
(n = 3), low (n = 5) and normal (n = 5) hMLH1 expres-
sion samples to study the methylation status of the 
hMLH1 gene promoter. No differences in average meth-
ylation percentage values between the three groups were 
observed, and all cases were found to be unmethylated 
(data not shown). Also, in the three cases where expres-
sion was absent and two cases with low levels, adjacent 
normal tissues were analysed. However, hypermethyla-
tion was not detected in the hMLH1 promoter of both 
tumoural and normal tissues (Additional file  2: Figure 
S1).
MSI was examined using a panel of five mononu-
cleotide markers (BAT 25, BAT 26, NR 21, NR 24 and 
MONO 27). None of the samples analyzed met the cri-
teria for MSI.
EGFR immunostaining and genomic DNA analysis of exons 
19, 20, 21
Immunostaining for EGFR was performed as described 
above. Seventeen (30.4%) out of 56 tumours analysed 
showed positive immunoreactivity to EGFR (Table  2). 
Different percentages of positive cases were found among 
different histologies: 7 (26%) of 27 seminomas, 2 (66.6%) 
of 3 teratomas, 8 (36.4%) of 22 EC and none of 4 yolk sac 
tumours studied. Moreover, different patterns of expres-
sion were evident: seminoma tumours showed membra-
nous immunoreactivity exclusively in the parenchyma 
cells (Fig.  1e); embryonal tumours showed immunore-
activity restricted to the stroma instead of parenchyma 
(Fig.  1f ); teratoma specimens showed immunoreactivity 
only in the epithelial components and not in mesenchy-
mal teratomatous cells (data not shown).
None of the 56 cases assessed showed EGFR mutations 
in exon 19, 20 or 21.
Assessment of risk factors and RFS
Univariate analysis showed that classical factors (rete 
testis invasion, tumour size ≥4  cm, LVI) were signifi-
cantly associated with a higher risk of relapse in our 
series (Table  3A). Rete testis invasion or tumor size 
≥4 cm in seminoma group and LVI or percentage ≥50% 
of EC in non seminoma group were significantly associ-
ated with higher risk of relapse (Additional file 3: Table 
S3). In addition, EI was associated with higher risk of 
relapse [Hazard Ratio (HR) 3.6; 95% confidence interval 
(CI) 1.4–9.3; p = 0.008] in our series (Table 3A; Fig. 2a). 
EI also showed a trend for higher risk of relapse when 







 Standard deviation 8.5
 Histology
  Seminoma 27 (48.2)
  Pure EC 10 (19.6)
  Pure Yolk Sac tumor 1 (1.9)
  Mixed tumor 18 (32.1)
Tumor diameter
 ≥4 cm 26 (46.4)
 <4 cm 27 (48.2)
 Unknown 3 (5.4)
Vascular and lymph vessels invasion
 Yes 16 (28.6)
 No 38 (67.8)
 Unknown 2 (3.6)
Presence of EC
 ≥50% 22 (39.2)
 <50% 33 (58.9)
   Unknown  1 (1.9)
Rete testis invasion
 Yes 18 (32.1)
 No 34 (60.7)
 Unknown 4 (7.1)
Epididymis invasion
 Yes 8 (14.3)
 No 48 (85.7)
 Unknown 0 (0)
Stage
 IA 27 (48.2)
 IB 11 (19.6)
 IS 17 (30.3)
Unknown 1 (1.9)
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patients were stratified by histological subtypes, how-
ever it was not statistically significant (Additional file 3: 
Table S3). 
There was a significant association between EGFR 
expression and higher risk of relapse. At 5-years, in the 
EGFR+ group the RFS was 52.9% in contrast with 82.1% 
in the EGFR− group (HR 3.5; 95% CI 1.3–9.8; p = 0.016) 
(Table 3A; Fig. 2b). Similar results were found when sem-
inoma and non seminoma groups were analyzed (Addi-
tional file  1: Table S3). hMLH-1 or hMSH2 expression 
did not show a significant relation with risk of relapse in 
our series and neither by histological subtypes (Table 3A; 
Additional file 3: Table S3).
A multivariate analysis identified EI as an independ-
ent predictor of outcome (HR 7.6; 95% CI 2.4–23.7; 
p = 0.001) (Table 3B).
Discussion
A surveillance strategy with chemotherapy at relapse has 
been shown to be a valid alternative to retroperitoneal 
lymphadenectomy, radiotherapy or adjuvant chemother-
apy in patients with CS I TGCT after inguinal orchiec-
tomy. Such a strategy has no impact on overall survival 
and avoids unnecessary treatment-related toxicity [2, 
29]. Recent data have encouraged the use of risk-adapted 
management strategies [30]. Nevertheless, the absence of 
precise markers to predict risk of relapse in each patient 





Fig. 1 Representative immunohistochemistry images of hMLH1, hMSH‑2 and EGFR protein expression. Nuclear hMLH1 staining in tumours with 
“low” (a) and “normal” (b) expression. Representative hMSH‑2 staining in tumour with “low” (c) and “normal” (d) expression. A seminoma (e) and 
embryonal carcinoma (f) showing positivity for EGFR staining. A high‑power view of the boxed regions is shown in the insets. Nuclear and mem‑
brane signal (brown) is visualized with diamino‑benzidine as chromogen. The black arrowhead depict EGFR immunoreactivity in the membrane of a 
seminoma cell. The red arrowhead shows nuclear hMLH1 signal
Table 2 Summary of  immunohistochemistry showing 
hMLH-1, hMSH-2 and EGFR expression
Expression No. patients (N = 56) (%)
hMLH‑1
 Null 4 7.1
 Low 23 41.1
 Normal 29 51.8
hMSH‑2
 Null 1 1.9
 Low 15 26.7
 Normal 40 71.4
EGFR
 Positive 17 30.4
 Negative 39 69.6
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Pathological features, previously reported as useful pre-
dictors of poor outcome in TGCT have been correlated 
in the present study with a higher risk of relapse. Further-
more, in multivariate analysis an independent association 
of epididymis invasion and higher risk of relapse has been 
shown. Epididymis invasion has previously been reported 
as a significant prognostic factor by Hoskins et al. and in 
the Medical Research Council prospective studies [4, 31]. 
Nonetheless, in neither of these studies was this factor 
shown to have an independent value in the multivariate 
analyses. To our knowledge ours is the first study to show 
that this factor has an independent relationship with RFS.
We studied MMR expression based on previous 
research reporting loss of hMLH1 and hMSH2 expres-
sion as being of prognostic significance in TGCT [12–14]. 
Our results show absent, low and normal hMLH1 and 
hMSH2 expression in proportions similar to those found 
in other studies [11, 32, 33] (Table  2). Studies in colon 
cancer have found the hMLH-1 promoter to be hyper-
methylated in 30% of sporadic cases with loss of hMLH1 
expression. Epigenetic modifications may explain differ-
ent levels of protein expression and an early study has 
reported a 5.7% rate of hMLH1 promoter methylation in 
TGCTs [34]. Consequently, we decided to study hMLH-1 
promoter methylation status in selected cases with 
absent, low and normal hMLH1 expression. However, all 
the studied cases were unmethylated. Therefore, another 
epigenetic deregulation or somatic mutation could be the 
cause of the lack of expression in our TGCT cases. Fur-
ther investigation in this line is currently ongoing.
In contrast with Velasco et  al. [13], in our experience 
there was no relationship between null/low hMLH1 
expression and risk of relapse. The reason could be due 
to genetic differences between the two populations stud-
ied (caucasian vs american-caucasian) or to differences in 
the treatment management, as in the Velasco et  al. [13] 
study some patients received chemotherapy prior to sur-
gery. Well-designed prospective studies are necessary to 
validate hMLH1 as a useful prognostic factor. In rela-
tion with hMSH-2, our findings are in agreement with 
Table 3 Survival analysis
Variable Relapse‑free survival
5 years‑RFS (%) HR (95% CI) p value
A. Univariate analysis
Histology
 NS 59.1 4.8 (1.4–16.3) 0.012
 Seminoma 90.3 1
Age
 ≤30 61.5 2.5 (1–6.5) 0.056
 >30 83.3 1
LVI
 Yes 54.5 3.2 (1.3–8.2) 0.014
 No 83.0 1
Tumor size (cm)
 ≥4 57.1 4.5 (1.5–13.5) 0.008
 <4 87.9 1
Rete testis invasion
 Yes 54.5 4.5 (1.5–13.3) 0.006
 No 88.4 1
Epididymis invasion
 Yes 25.0 3.6 (1.4–9.3) 0.008
 No 81.3 1
hMLH1 expression
 Null/low 66.7 2 (0.7–5.7) 0.178
 Normal 79.3 1
hMSH2 expression
 Null/low 81.3 0.66 (0.2–2.3) 0.524
 Normal 70.0 1
EGFR expression
 Positive 52.9 3.5 (1.3–9.8) 0.016
 Negative 82.1 1
Variable Relapse‑free survival


















HR (95% CI) p value
Epididymis invasion
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previous reports confirming the absence of relationship 
between its expression and risk of relapse [13].
hMLH1 and hMSH2 are responsible for genetic sta-
bility and a lack of these proteins could generate a spe-
cial type of genetic instability known as MSI. Because 
we found null/low expression of MMR proteins in some 
cases, we decided to study the MSI status of our TGCT 
cases. Nevertheless, we did not find MSI in any of our 
56 CS I TGCT cases. This result contrasts with previ-
ous studies that have reported MSI in 10–30% of TGCT. 
Most of these studies analysed II–IV stage TGCT cases 
and also some cisplatin treated patients were included 
[12, 14, 33]. In contrast, we selectively studied clinical 
stage I patients without previous chemotherapy. Dif-
ferent stages of TGCT could be critical in the appear-
ance of MSI, as this process needs time to develop from 
MMR deficiency to the appearance of MSI. Further-
more, MSI might be secondary to chemotherapy and 
thus should be studied in samples from chemotherapy-
naive patients.
EGFR expression was analysed in our series based 
on previous reports of EGFR overexpression in TGCT 
cases [18–23] and its value as a prognostic factor in 
other tumours [16, 35]. We found that almost one-third 
of the TGCT samples studied showed EGFR expres-
sion by IHC. Moreover, we found that 47% of EGFR+ 
patients relapsed 5-years postorchiectomy, in contrast 
with 18% of patients without EGFR immunoreactivity 
who relapsed during this period (Table  3A). Similarly, 
Miyai et al. [36] published the result of an EGFR study 
in 209 histologically distinct components from 110 
TGCT cases wherein 35 (32%) showed immunoreactiv-
ity to EGFR. This study suggests that EGFR expression 
may be involved in the progression from “pre-invasive” 
lesions (IGCNU) to invasive lesions, because its expres-
sion is absent in the IGCNU tissue and is more frequent 
in choriocarcinoma, which represents a more aggres-
sive phenotype of TGCTs. Also, previous studies have 
suggested the possible oncogenic potential of EGFR in 
adult TGCTs [18]. The present work describes a signifi-
cant correlation between the expression of EGFR and 
higher risk of relapse in early stage TGCTs after orchi-
ectomy, which might constitute further proof of the 
possible oncogenic potential of EGFR in TGCTs. To our 
knowledge ours is the first study to report a significant 
relationship between EGFR expression and higher risk 
of relapse in TGCT.
The most important limitation of this study is the sam-
ple size. Due to this limitation, we could not assess the 
prognosis value of EGFR expression among different 
TGCT histologies. This could be a possible explanation 
of the poor relationship between EGFR expression and 
the risk of relapse in multivariate analysis. Further stud-
ies with a larger representation for each TGCT subtype 
would be needed to evaluate the prognosis value of EGFR 
expression in these tumours.
Fig. 2 Kaplan–Meier curves representing survival of TGCT patients stratified by epididymis invasion presence (a) or EGFR expression (b). Differences 
between the two curves were calculated using the log‑rank tests and resultant p value is shown in each graph. EI epididymis invasion, NS Non‑
seminoma, ns not significant
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Conclusions
Mismatch repair proteins and microsatellite analysis 
did not correlate in this study with clinical outcome. 
Epididymis invasion and EGFR expression have shown a 
potential value as new risk factors of recurrence in CS I 
TGCT, which deserves to be confirmed in a prospective 
and larger analysis.
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